Back to search results

Vimseltinib for Chronic Graft-Versus-Host Disease (cGVHD)

This study is testing a medication called vimseltinib in adults with active chronic Graft-Versus-Host Disease (cGVHD). cGVHD is a condition that can happen after a stem cell transplant where the new immune cells attack the patient's body. The main goals of this study are to see if vimseltinib is safe, how well people tolerate it, and if it helps treat moderate to severe cGVHD. You might be able to join if you've had a stem cell transplant, have active cGVHD, and have already tried at least two other treatments that didn't work. Researchers will be looking at side effects and serious side effects to understand the safety of vimseltinib over about two years.

Study design
This is an interventional study planning to enroll 48 participants to evaluate vimseltinib.
What's involved
Participants will take vimseltinib orally in 28-day cycles for approximately two years.
Compensation
Not stated in the trial record.
Follow-up
Safety will be monitored from the start of the study until its estimated completion, which could be up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06619561

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Deciphera Pharmaceuticals, LLC
~48 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:Vimseltinib

At a glance

Recruiting sites
26 of 26 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Dose-Limiting Toxicities (DLTs)
Measured over Cycle 1 (28 Days)
+1 more outcome measured

Conditions

Chronic Graft-Versus-Host Disease (cGVHD)

Explore related trials

Chronic Graft Versus Host Disease

NCT06619561

Where you'd take part

This study runs at 26 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AdventHealth Orlando

    Orlando, Floridano site contact published

    Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakotano site contact published

    Recruiting

  • City of Hope National Medical Center

    Duarte, Californiano site contact published

    Recruiting

  • Cleveland Clinic

    Cleveland, Ohiono site contact published

    Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusettsno site contact published

    Recruiting

  • Duke University Hospital

    Durham, North Carolinano site contact published

    Recruiting

  • Emory University Winship Cancer Institute

    Atlanta, Georgiano site contact published

    Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michiganno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Clinical Team · STUDY_DIRECTOR · Deciphera Pharmaceuticals, LLC

Who to contact

Clinical Team
[email protected]
888-724-3274
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Number of Participants with Dose-Limiting Toxicities (DLTs)Cycle 1 (28 Days)

    DLTs assessed for each dose level.

  • Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)Baseline to Study Completion (Estimated up to 24 months)

    AEs and SAEs assessed for each dose level.